3880 Stock Chart & Stats
HK$30.00
--
Market closed
HK$30.00
--
Day’s Range― - ―
52-Week RangeHK$19.00 - HK$41.72
Previous CloseN/A
VolumeN/A
Average Volume (3M)155.10K
Market Cap
HK$3.12B
Enterprise ValueHK$3.16K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)14.0
Beta0.62
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.89
Shares Outstanding141,800,000
10 Day Avg. Volume149,470
30 Day Avg. Volume155,096
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.82
Revenue Forecast (FY)HK$684.10M
Medtide, Inc. Class H News
3880 FAQ
What was Medtide, Inc. Class H’s price range in the past 12 months?
Medtide, Inc. Class H lowest stock price was HK$19.00 and its highest was HK$41.72 in the past 12 months.
What is Medtide, Inc. Class H’s market cap?
Medtide, Inc. Class H’s market cap is HK$3.12B.
When is Medtide, Inc. Class H’s upcoming earnings report date?
Medtide, Inc. Class H’s upcoming earnings report date is Aug 27, 2026 which is in 8 days.
How were Medtide, Inc. Class H’s earnings last quarter?
Medtide, Inc. Class H released its earnings results on Mar 30, 2026. The company reported HK$0.891 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Medtide, Inc. Class H overvalued?
According to Wall Street analysts Medtide, Inc. Class H’s price is currently Overvalued.
Does Medtide, Inc. Class H pay dividends?
Medtide, Inc. Class H does not currently pay dividends.
What is Medtide, Inc. Class H’s EPS estimate?
Medtide, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medtide, Inc. Class H have?
Medtide, Inc. Class H has 141,800,000 shares outstanding.
What happened to Medtide, Inc. Class H’s price movement after its last earnings report?
Medtide, Inc. Class H reported an EPS of HK$0.891 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.189%.
Which hedge fund is a major shareholder of Medtide, Inc. Class H?
Currently, no hedge funds are holding shares in HK:3880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medtide, Inc. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
61.78%
Trailing 12-Months
Company Description
Medtide, Inc. Class H
Medtide Inc. operates as a contract research, development, and manufacturing organization (CRDMO), providing comprehensive services across the entire pharmaceutical lifecycle, from initial drug discovery and preclinical investigation through to clinical development and commercial-scale production. The company specializes in the synthesis of novel peptide chemical entities for discovery purposes, along with the development of peptide-based chemistry, manufacturing, and control (CMC) processes, and their subsequent commercial manufacturing. A core area of its developmental focus is on glucagon-like peptide-1 (GLP-1) molecules, which it designs for both oral and/or injectable administration. Medtide leverages a suite of proprietary research and development platforms, including OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. Its client base spans multiple regions globally, including China, the United States, Japan, Europe, South Korea, and Australia. Established in 2020 as Taide Pharmaceutical (Zhejiang) Co., Ltd, the company rebranded to Medtide Inc. in February 2023 and maintains its headquarters in Hangzhou, China.
Technical Analysis
Genor Biopharma Holdings Limited
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
Viva Biotech Holdings
―
Clover Biopharmaceuticals Ltd.
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―